Horizon Pharmaceutical 10-Q/A 12 May 14 2013 Q3 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Apr. 30, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Raptor Pharmaceutical Corp	'
Entity Central Index Key	'0001070698	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	62,616,859
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Amendment Flag	'true	'
Amendment Description	'As previously disclosed by Raptor Pharmaceutical Corp., or the “Company,” in its current report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “Commission”) on January 22, 2014, the Company has engaged Grant Thornton LLP (“Grant Thornton”) to replace Burr Pilger Mayer, Inc. (“BPM”) to serve as the Company’s independent registered public accounting firm. The Company is filing this Amendment No. 1 (the “Form 10-Q/A”) to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2013, filed with the Commission on November 7, 2013 (the “Form 10-Q”), to include Grant Thornton’s review report with respect to the interim financial statements included in this Form 10-Q/A. In addition to the changes to the financial statements and notes thereto included in this Form 10-Q/A, which are to conform to the presentation of the 2013 financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (filed with the Commission on March 17, 2014), the Company has amended Part I, Item 2 to delete its previous disclosure relating to an explanatory paragraph regarding the Company’s ability to continue as a going concern because this explanatory paragraph was removed from BPM’s reissued reports for such periods due to changes in the Company’s circumstances. Except as specifically noted above, this Form 10-Q/A does not modify or update disclosures in the Form 10-Q, and there have been no other material changes to the disclosures made in the Form 10-Q as of the filing of the Form 10-Q. Accordingly, except as specifically noted above, this Form 10-Q/A does not reflect events occurring after the filing of the Form 10-Q or modify or update any related or other disclosures.	'
Document Period End Date	30-Sep-13	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Aug. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'	'
Cash and cash equivalents	$88,334	$36,313	$23,580
Restricted cash	500	163	'
Short-term investments	0	22,096	'
Accounts receivable, net	5,519	0	'
Inventories, net	2,218	0	'
Prepaid expenses and other	2,764	1,610	'
Total current assets	99,335	60,182	'
Intangible assets, net	3,272	2,156	'
Goodwill	3,275	3,275	'
Fixed assets, net	1,309	416	'
Deposits	153	26	'
Other assets	172	109	'
Debt issuance costs	2,929	1,959	'
Total assets	110,445	68,123	'
Current liabilities:	'	'	'
Accounts payable	1,847	4,599	'
Accrued liabilities	9,260	2,150	'
Deferred revenue	3,010	0	'
Common stock warrant liability	10,339	16,405	'
Deferred rent	157	6	'
Capital lease liability - current	18	8	'
Total current liabilities	24,631	23,168	'
Note payable	50,000	25,000	'
Capital lease liability - long-term	45	11	'
Total liabilities	74,676	48,179	'
Commitments and contingencies - see Note 8	'	'	'
Stockholders' equity:	'	'	'
Preferred stock, $0.001 par value per share,15,000,000 shares authorized, zero shares issued and outstanding	0	0	'
Common stock, $0.001 par value per share, 150,000,000 shares authorized 61,142,756 and 52,424,649 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	61	52	'
Additional paid-in capital	229,164	155,945	'
Accumulated other comprehensive loss	-193	-115	'
Accumulated deficit	-193,263	-135,938	'
Total stockholders' equity	35,769	19,944	'
Total liabilities and stockholders' equity	$110,445	$68,123	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Stockholders' Equity	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock issued (in shares)	61,142,756	52,424,649
Common stock, shares outstanding (in shares)	61,142,756	52,424,649

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Aug. 31, 2012	Sep. 30, 2013	Aug. 31, 2012
Condensed Consolidated Statements Of Comprehensive Loss (Unaudited) [Abstract]	'	'	'	'
Net product sales	$6,603	$0	$6,624	$0
Operating expenses:	'	'	'	'
Cost of sales	442	0	867	0
Research and development	6,791	6,436	21,418	16,427
Selling, general and administrative	8,334	5,830	25,576	12,387
Total operating expenses	15,567	12,266	47,861	28,814
Loss from operations	-8,964	-12,266	-41,237	-28,814
Interest income	3	78	174	276
Interest expense	-2,287	-1	-4,088	-2
Foreign currency transaction gain/ (loss)	15	23	-20	86
Gain (loss) on short-term investments	0	72	-129	248
Adjustment to fair value of common stock warrants	-6,044	1,872	-12,025	995
Net loss	-17,277	-10,222	-57,325	-27,211
Other comprehensive gain (loss):	'	'	'	'
Foreign currency translation adjustment	11	-34	-78	-43
Comprehensive loss	($17,266)	($10,256)	($57,403)	($27,254)
Net loss per share:	'	'	'	'
Basic and diluted (in dollars per share)	($0.29)	($0.21)	($1.01)	($0.56)
Weighted-average shares outstanding used to compute:	'	'	'	'
Basic and diluted (in shares)	59,964	49,766	56,658	48,899

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
In Thousands, except Share data
Balance at Dec. 31, 2012	$52	$155,945	($115)	($135,938)	$19,944
Balance (in shares) at Dec. 31, 2012	52,425	'	'	'	'
Exercise of common stock warrants	3	9,806	0	0	9,809
Exercise of common stock warrants (in shares)	3,401	'	'	'	3,400,725
Exercise of common stock options	1	1,515	0	0	1,516
Exercise of common stock options (in shares)	378	'	'	'	378,366
Employee stock-based compensation expense	0	5,417	0	0	5,417
Consultant stock-based compensation expense	0	3	0	0	3
Reclassification of the fair value of warrant liabilities upon exercise	0	18,091	0	0	18,091
Issuance of common stock under an at-the-market sales agreement, net of commissions and fundraising costs of $1,572	5	38,387	0	0	38,392
Issuance of common stock under an at-the-market sales agreement, net of commissions and fundraising costs totaling $1,572 (in shares)	4,939	'	'	'	'
Foreign currency translation loss	0	0	-78	0	-78
Net loss	0	0	0	-57,325	-57,325
Balance at Sep. 30, 2013	$61	$229,164	($193)	($193,263)	$35,769
Balance (in shares) at Sep. 30, 2013	61,143	'	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parenthetical) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) [Abstract]	'
Commissions and fundraising costs on issuance of shares	$1,572

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Aug. 31, 2012
Cash flows from operating activities:	'	'
Net loss	($57,325)	($27,211)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Employee stock-based compensation expense	5,417	3,570
Consultant stock-based compensation expense	3	72
Fair value adjustment of common stock warrants	12,025	-995
Amortization of intangible assets	134	109
Depreciation of fixed assets	152	32
Realized (gain) on sale of fixed assets	-12	0
(Gain) loss on short-term investments	129	-248
Amortization of debt issuance costs	289	0
Write-off of intangible assets and other intellectual property	0	900
Changes in assets and liabilities:	'	'
Accounts receivable, net	-5,519	0
Inventories, net	-2,218	0
Prepaid expenses and other	-1,154	-2,781
Intangible assets	-1,250	0
Deposits	-127	0
Accounts payable	-2,752	-664
Accrued liabilities	7,110	994
Deferred revenue	3,010	0
Deferred rent	151	-7
Net cash used in operating activities	-41,937	-26,229
Cash flows from investing activities:	'	'
Purchase of fixed assets	-992	-351
Sale of fixed assets	27	0
Change in restricted cash	-337	-56
Purchase of short-term investments	-147	-15,040
Sale of short-term investments	22,114	30,000
Net cash provided by investing activities	20,665	14,553
Cash flows from financing activities:	'	'
Proceeds from the sale of common stock under an ATM sales agreement	38,392	7,324
Proceeds from the exercise of common stock warrants	9,809	3,057
Proceeds from the exercise of common stock options	1,516	325
Note payable	25,000	0
Debt issuance costs	-1,259	0
Offering costs	-63	-134
Payments on capital leases	-24	-5
Net cash provided by financing activities	73,371	10,567
Effect of exchange rates on cash and cash equivalents	-78	-43
Net increase (decrease) in cash and cash equivalents	52,021	-1,152
Cash and cash equivalents, beginning of period	36,313	24,732
Cash and cash equivalents, end of period	88,334	23,580
Supplemental cash flow information:	'	'
Interest paid	2,314	3
Supplemental disclosure of non-cash financing activities:	'	'
Fair value of warrant liability reclassified to equity upon exercise	18,091	7,106
Acquisition of equipment in exchange for capital lease	$68	$13

DESCRIPTION_OF_BUSINESS_AND_SI

DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES	'
	1. DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
	Raptor Pharmaceutical Corp. (the "Company" or "Raptor") is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases.
	The Company's first product, PROCYSBI® (cysteamine bitartrate) delayed-release capsules ("PROCYSBI"), received approval from the U.S. Food and Drug Administration ("FDA") on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older.  The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), received marketing authorization on September 6, 2013 from the European Commission ("EC") as an orphan medicinal product for the treatment of proven nephropathic cystinosis for marketing in the European Union ("EU"). PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively.  The Company commenced commercial sales of PROCYSBI in the U.S. in mid-June 2013 and plans to launch PROCYSBI in the EU in the first half of 2014.  Prior to the second quarter of 2013, the Company had been in its development stage.  With FDA approval of PROCYSBI and the commencement of commercial sales in the second quarter of 2013, the Company was no longer considered to be in the development stage.  In the near-term, the Company's ability to generate revenues is entirely dependent upon sales of PROCYSBI in the U.S. and the EU.
	Raptor's pipeline also includes its proprietary delayed-release form of cysteamine (DR Cysteamine or "RP103") in Phase 2/3 development for Huntington's disease and RP103 in Phase 2b development for nonalcoholic fatty liver disease ("NAFLD") in children.  Raptor's other preclinical programs are based upon novel drug candidates that are designed to treat primary liver cancer and various other diseases.
	The Company is subject to a number of risks, including: the level of commercial sales of PROCYSBI in the U.S. and the ability to launch PROCYSBI in the EU; the uncertainty of whether the Company's research and development efforts will result in expanded indications for PROCYSBI or additional commercial products; competition from larger organizations; reliance on licensing the proprietary technology of others; dependence on key personnel; uncertain patent protection; and the need to raise capital through equity and/or debt financings.  Funding may not be available when needed if at all or on terms acceptable to the Company. If the Company exhausts its cash reserves and is unable to obtain adequate financing, it may be required to curtail planned operating expenditures, including its development programs.
	Change in Fiscal Year End
	In December 2012, Raptor's board of directors approved a change in the Company's fiscal year end from August 31 to December 31, effective on December 31, 2012.  The accompanying condensed consolidated financial statements cover the period from January 1, 2013 through September 30, 2013, representing the first nine months of Raptor's recently adopted fiscal year.  The prior year's comparable nine-month period covers December 1, 2011 through August 31, 2012, which is reported on the basis of Raptor's previous fiscal year end.  As a result of the change in Raptor's fiscal year end, the quarterly periods of Raptor's newly adopted fiscal year do not coincide with the historical quarterly periods that Raptor had previously reported.
	Basis of Presentation
	The accompanying condensed consolidated financial statements reflect the results of operations of Raptor and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).  Certain information and footnotes have been condensed or omitted pursuant to such rules and regulations.  The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments (including normal recurring adjustments) considered necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. The condensed consolidated balance sheet as of December 31, 2012 has been derived from the Company’s audited financial statements as of such date, but does not include all disclosures required by GAAP. This Form 10-Q/A should be read in conjunction with the audited financial statements and accompanying notes in the Company's Transition Report on Form 10-KT/A for the four-month period ended December 31, 2012, as amended.
	The Company's condensed consolidated financial statements include the accounts of the Company's direct and indirect wholly owned subsidiaries, Raptor Pharmaceuticals Inc., formerly known as Raptor Therapeutics Inc. which merged with Raptor Discoveries Inc. in December 2012 prior to changing its name and Raptor European Products, LLC, such subsidiaries incorporated in Delaware on August 1, 2007, and February 14, 2012, respectively, and Raptor Pharmaceuticals Europe B.V. (domiciled in the Netherlands and formed on December 15, 2009), Raptor Pharmaceuticals France SAS (incorporated in France on October 30, 2012), Raptor Pharmaceuticals Germany GmbH (formed on September 28, 2013 and incorporated in Germany as a German company with limited liability on October 15, 2013) and RPTP European Holdings C.V. (located in the Grand Caymans and formed on February 16, 2012).  All intercompany accounts have been eliminated.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
	Revenue Recognition and Accounts Receivable
	The Company recognizes revenue in accordance with the FASB ASC 605, Revenue Recognition, when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed; the price is fixed or determinable and collectability is reasonably assured.  The Company determines that persuasive evidence of an arrangement exists based on written contracts that define the terms of the arrangements.  Pursuant to the contract terms, the Company determines when title to products and associated risk of loss has passed onto the customer.  The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment.  The Company assesses collectability based primarily on the customer's payment history and creditworthiness.
	PROCYSBI is currently only available for distribution from the Company's U.S. specialty pharmacy partner, Accredo Health Group, Inc. ("Accredo"), which is currently the Company’s only customer and ships directly to patients.  PROCYSBI is not available in retail pharmacies.  Prior authorization of coverage level by patients' private insurance plans, our patient assistance program ("PAP") or government payors is a prerequisite to the shipment of PROCYSBI to patients.  Revenue is recognized once the product has been shipped by the specialty pharmacy to patients because the Company is unable to reasonably estimate the third-party payor mix and resulting rebates based on its lack of sufficient historical data.  Billings to the Company's distributor in advance of product shipment and delivery by the specialty pharmacy to patients are recorded as deferred revenues by the Company until such shipments to patients occur.
	The Company records revenue net of expected returns, discounts, distributor fees, rebates, including those paid to U.S. government agencies.  Allowances are recorded as a reduction of revenue at the time product sales are recognized.  Allowances for government rebates and discounts are established based on the actual payor information, which is known at the time of shipment to patients, and the government-mandated discounts applicable to government-funded programs.  The allowances are adjusted to reflect known changes in the factors that may impact such allowances in the quarter the changes are known.
	Trade accounts receivable are recorded net of product sales allowances for prompt-payment discounts and chargebacks.  Estimates for chargebacks and prompt-payment discounts are based on contractual terms and the Company's expectations regarding the utilization rates.
	Inventories and Cost of Sales
	Inventories are stated at the lower of cost or market price, with cost determined on a first-in, first-out basis.  Inventories are reviewed periodically to identify slow-moving inventory based on sales activity, both projected and historical, as well as product shelf-life.   Prior to the approval of PROCYSBI by the FDA on April 30 2013, the Company recorded the purchase of raw materials and the manufacturing costs relating to PROCYSBI as research and development expense.  Subsequent to approval, the Company began capitalizing these costs as commercial inventory.  As of September 30, 2013, net inventories were approximately $2.2 million, which consisted of $1.8 million of raw materials, $0.3 million of work-in-process and $0.5 million of finished goods, offset by a reserve allowance of $0.4 million.  Upon launching PROCYSBI in mid-June 2013, the Company began recognizing cost of sales.  During the second quarter ended June 30, 2013, the Company recorded a $0.4 million reserve as cost of sales expense representing commercial inventory that was capitalized subsequent to FDA approval but written off due to an unanticipated minor change in the finished product presentation.  No write-off occurred in the third quarter.  Cost of sales includes the cost of inventory sold and reserved, manufacturing and supply chain costs, product shipping and handling costs, amortization of licensing approval milestone payments and licensing royalties payable to the University of California, San Diego ("UCSD").
	Comprehensive Loss
	The components of comprehensive loss include net loss and foreign currency translation adjustments.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents.  The Company maintains cash and cash equivalents, which consist principally of money market funds with high credit quality financial institutions.  Such amounts exceed Federal Deposit Insurance Corporation insurance limits.  Restricted cash represents compensating balances required by the Company's U.S. bank as collateral for credit cards.
	Short-term Investments
	The Company typically invests in short-term investments in high credit-quality funds in order to obtain higher yields on its cash available for investment.  The Company had no short-term investments at September 30, 2013 compared to approximately $22.1 million at December 31, 2012.  The Company regularly evaluates its short-term investment fund options and in the future may invest a portion of its cash and cash equivalents balance ($88.3 million as of September 30, 2013) in higher credit-quality and higher-yielding short-term investment funds.
	Such investments are not insured by the Federal Deposit Insurance Corporation.  The Company completed an evaluation of its investments and determined that it did not have any other-than-temporary impairments as of September 30, 2013 or December 31, 2012.
	Functional Currency
	The Company's consolidated functional currency is the U.S. dollar.  Raptor Pharmaceuticals Europe B.V. ("BV"), Raptor Pharmaceuticals France SAS ("SAS") and RPTP European Holdings C.V. ("CV"), the Company's European subsidiaries and Cayman-based subsidiary, respectively, use the European Euro as their functional currency.  At each quarter end, each foreign subsidiary's balance sheets are translated into U.S. dollars based upon the quarter-end exchange rate, while their statements of operations and comprehensive loss are translated into U.S. dollars based upon an average exchange rate.
	Fair Value of Financial Instruments
	The carrying amounts of certain of the Company's financial instruments including cash equivalents, restricted cash, accounts payable, accrued liabilities, note payable and capital lease liability approximate fair value due either to length of maturity or interest rates that approximate prevailing market rates. The warrant liability is carried at fair value which is determined using the Black-Scholes option valuation model at the end of each reporting period.
	The Company uses a fair value approach to value certain assets and liabilities.  Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The hierarchy consists of three levels:
		·	Level one - Quoted market prices in active markets for identical assets or liabilities;
		·	Level two - Inputs other than level one inputs that are either directly or indirectly observable; and
		·	Level three - Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.  Assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 are summarized as follows:
	(In thousands)
	Assets		Level 1		Level 2		Level 3		September 30,
									2013
	Fair value of cash equivalents		$	71,434	$	0	$	0	$	71,434
	Total		$	71,434	$	0	$	0	$	71,434
	Liabilities
	Fair value of common stock warrants		$	0	$	0	$	10,339	$	10,339
	Total		$	0	$	0	$	10,339	$	10,339
	Assets		Level 1		Level 2		Level 3		31-Dec-12
	Fair value of cash equivalents		$	35,069	$	0	$	0	$	35,069
	Short-term investments			22,096		0		0		22,096
	Total		$	57,165	$	0	$	0	$	57,165
	Liabilities
	Fair value of common stock warrants		$	0	$	0	$	16,405	$	16,405
	Total		$	0	$	0	$	16,405	$	16,405
	See Note 5 for further discussion of the calculation of the fair value of the common stock warrant liability.
	Intangible Assets
	Intangible assets primarily include the intellectual property and other rights relating to DR Cysteamine (developed as PROCYSBI/RP103), and an out-license acquired in a 2009 Merger.  The other intangible assets related to PROCYSBI/RP103 are amortized using the straight-line method over the estimated useful life of 20 years, which is the life of the intellectual property patents.  The 20-year estimated useful life is also based upon the typical development, approval, marketing and life cycle management timelines of pharmaceutical drug products.   Intangible assets related to the out-license are amortized using the straight-line method over the estimated useful life of 16 years, which is the life of the intellectual property patents.
	Segment Information
	The Company has determined that it operates in only one segment, as it only reports profit and loss information on an aggregate basis to its chief operating decision maker. The Company’s long-lived assets maintained outside the U.S. are not material.
	Fixed Assets
	Fixed assets, which mainly consist of leasehold improvements, furniture and fixtures, lab equipment, computer hardware and software and capital lease equipment, are stated at cost.  Depreciation is computed using the straight-line method over the related estimated useful lives, except for leasehold improvements and capital lease equipment, which are depreciated over the shorter of the useful life of the asset or the lease term. Significant additions and improvements that have useful lives estimated at greater than one year are capitalized, while repairs and maintenance are charged to expense as incurred.
	Impairment of Goodwill and Long-Lived Assets
	Goodwill represents the excess of purchase price over the fair value of tangible and identified intangible assets of businesses acquired. Goodwill is not amortized, but is evaluated for impairment on an annual basis or more often when impairment indicators are present. When an impairment analysis is performed, if deemed necessary, a write-down in valuation is recorded.
	The Company has one reporting unit. Therefore, the Company’s consolidated net assets, including existing goodwill and other intangible assets, are considered to be the carrying value of the reporting unit. If the carrying value of the reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the analysis, in which the implied fair value of the goodwill is compared to its carrying value to determine the impairment charge, if any. If the estimated fair value of the reporting unit exceeds the carrying value of the reporting unit, goodwill is not impaired and no further analysis is required.
	The Company makes judgments about the recoverability of purchased intangible assets with finite lives and other long-lived assets whenever events or changes in circumstances indicate that impairment may exist. Recoverability of purchased intangible assets with finite lives and other long-lived assets is measured by comparing the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. Impairment, if any, is measured as the amount by which the carrying value exceeds the fair value of the impaired asset.
	Accrued Liabilities
	Accrued liabilities include estimates of certain expenses for which the Company has not yet been invoiced and which requires management's judgment in determining appropriate expenses to accrue.   Although the Company believes its accrued liabilities reflect the best information available to it, the Company's actual expenses could differ from its estimates.
Common Stock Warrant Liabilities
The Company issued warrants that contain conditional obligations that may require the Company to transfer cash to settle the warrants upon the occurrence of certain fundamental transactions. Therefore, the Company has classified the warrants as liabilities.  The Company re-measures the liability at the end of every reporting period with the change in value reported in the Company’s consolidated statements of operations and comprehensive loss.  At the exercise date, the fair values of these warrants are re-measured and reclassified to equity.
Deferred Offering Costs
Deferred offering costs represent expenses incurred to raise equity capital related to financing transactions which have not yet been completed as of the balance sheet dates.
Note Payable and Debt Issuance Costs
Note payable consists of the Company's loan agreement with HealthCare Royalty Partners II, L.P. ("HC Royalty"), as lender, under which Raptor agreed to borrow $50.0 million in two $25.0 million tranches.  The Company received the first tranche in December 2012 and the second tranche in May 2013.  The loan bears interest at an annual fixed rate of 10.75% of outstanding principal and includes a synthetic royalty component based on net product sales, including PROCYSBI, in a calendar year.  The fixed and royalty interest are recognized as interest expense as incurred. Debt issuance costs, which were capitalized and included in other long-term assets, are being amortized over the life of the loan using the interest method.
Research and Development Costs
Research and development costs are charged to expense as incurred. Research and development expenses include medical, clinical, regulatory and scientists' salaries and benefits, lab collaborations, preclinical studies, clinical trials, clinical trial materials, commercial drug manufacturing expenses prior to obtaining marketing approval, regulatory and clinical consultants, lab supplies, lab services, lab equipment maintenance and small equipment purchased to support the research laboratory, amortization of intangible assets and allocated human resources and facilities expenses.
Income Taxes
Income taxes are recorded under the liability method, under which deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.  Based on the weight of available evidence, including cumulative losses since inception and expected future losses, the Company has determined that it is more likely than not that the deferred tax asset amount will not be realized and therefore a full valuation allowance has been provided on the Company’s net deferred tax assets.
The Company identifies uncertain tax positions and discloses any potential tax liability on its financial statements.  The Company recognizes interest and/or penalties related to income tax matters as a component of income tax expense.
As of September 30, 2013, there were no liabilities recorded related to uncertain tax positions and no accrued interest or penalties related to uncertain tax positions.
The Company files U.S. Federal, California, various other state income and other tax returns and various foreign country income tax returns.  The Company is currently not subject to any income tax examinations.  Due to the Company's net operating losses, generally all tax years remain open.
Net Loss per Share
Net loss per share is calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period.  Diluted net income per share is calculated by dividing net income by the weighted-average shares of common stock outstanding and potential shares of common stock during the period.  For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net loss per share as their effect is anti-dilutive.  Potentially dilutive securities include:
		Nine months ended
(In thousands)		30-Sep-13		31-Aug-12
Warrants to purchase common stock			1,145		5,188
Options to purchase common stock			8,230		6,125
Total potentially dilutive securities			9,375		11,313
Net loss per share, basic and diluted, was $(0.29) and $(0.21) for the three months ended September 30, 2013 and August 31, 2012, respectively, and $(1.01) and $(0.56) for the nine months ended September 30, 2013 and August 31, 2012, respectively.
Stock Option Plan
Compensation cost related to the Company’s stock option plans is measured at the grant date based on the fair value of the equity instruments awarded and is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award, or the requisite service period, which is usually the vesting period. The Company recognizes expense associated with stock options issued to third parties, including consultants, based upon the fair values of such awards on the dates the awards vest.
Reclassifications
Certain amounts previously reported under specific financial statement captions have been reclassified to be consistent with the current period presentation.

INTANGIBLE_ASSETS_AND_GOODWILL

INTANGIBLE ASSETS AND GOODWILL	9 Months Ended
	Sep. 30, 2013
INTANGIBLE ASSETS AND GOODWILL [Abstract]	'
INTANGIBLE ASSETS AND GOODWILL	'
	2. INTANGIBLE ASSETS AND GOODWILL
	On December 14, 2007, the Company acquired the intellectual property and other rights to develop PROCYSBI/RP103 to treat various clinical indications from the University of California at San Diego (“UCSD”) by way of a merger with Encode Pharmaceuticals, Inc., a privately held development stage company ("Encode"), which held the intellectual property license with UCSD. The fair value of the intangible assets acquired at the time of the acquisition was approximately $2.6 million.  Based upon FDA and EC approval of PROCYSBI, the Company paid and capitalized $750,000 and $500,000, respectively, earned by UCSD as a licensing milestone payment which is being amortized through 2027, the life of the licensed patents.
	Pursuant to the license agreement with UCSD, the Company is obligated to pay an annual maintenance fee until the commencement of commercial sales of any licensed products developed.  The Company is also obligated to pay milestone payments upon the occurrence of certain events, royalties on net sales from products developed pursuant to the license agreement and a percentage of sublicense fees or royalties, if any. The Company is obligated to fulfill predetermined milestones within a specified number of years from the effective date of the license agreement, depending on the indication. To the extent that the Company fails to perform any of the obligations, UCSD may terminate the license or otherwise cause the license to become non-exclusive.
	Intangible assets originally recorded as a result of a 2009 merger were approximately $1.1 million of which $0.9 million was written off to research and development expense during the year ended August 31, 2012, as discussed below.
	A summary of intangible assets acquired is as follows:
	(In thousands)	30-Sep-13			31-Dec-12
	Intangible asset (IP license for PROCYSBI/RP103) related to the Encode merger	$	2,620		$	2,620
	Intangible assets (out-license) related to the 2009 Merger		240			240
	Intangible assets (UCSD license FDA and EC approval milestones)		1,250			0
	Total intangible assets		4,110			2,860
	Less accumulated amortization		(838	)		(704	)
	Intangible assets, net	$	3,272		$	2,156
	At August 31, 2012, the Company determined that the capitalized acquired in-process research and development asset carried at $0.9 million, representing the tezampanel and NGX 426 program acquired in a 2009 merger, was fully impaired due to the Company's decision to discontinue development of this product candidate. During the three and nine months ended September 30, 2013, the Company did not identify any impairment losses.
	The Company amortized approximately $47,000 and $37,000 of intangible assets during the three-month periods ended September 30, 2013 and August 31, 2012, respectively, and $134,000 and $109,000 during the nine-month periods ended September 30, 2013 and August 31, 2012, respectively.  These amounts relate to the amortization of the intangible assets listed above which includes milestone fees earned by UCSD in the second and third quarters of 2013 of $750,000 and $500,000, respectively, upon the FDA and EC approval of PROCYSBI.
	Amortization expense for intangible assets for the periods indicated is expected to be as follows:
	Year ending December 31, (In thousands)	Amortization
		expense
	2013  (remaining 3 months)	$	194
	2014		238
	2015		238
	2016		238
	2017		238
	The Company tested the carrying value of goodwill for impairment as of the end of its transition period for the four month period ended December 31, 2012 and determined that there was no impairment.

FIXED_ASSETS

FIXED ASSETS	9 Months Ended
	Sep. 30, 2013
FIXED ASSETS [Abstract]	'
FIXED ASSETS	'
	3. FIXED ASSETS
	Fixed assets consisted of:
		September 30,			December 31,
	Category (In thousands)	2013			2012			Estimated useful lives
	Leasehold improvements	$	0		$	146		Shorter of life of asset or lease term
	Office furniture		497			35		7 years
	Laboratory equipment		902			593		5 years
	Computer hardware and software		426			204		3 years
	Capital lease equipment		68			27		Shorter of life of asset or lease term
	Total at cost		1,893			1,005
	Less: accumulated depreciation		(584	)		(589	)
	Total fixed assets, net	$	1,309		$	416
	Depreciation expense for the three months ended September 30, 2013 and August 31, 2012 was approximately $74,000, and $29,000, respectively.  Depreciation expense for the nine months ended September 30, 2013 and August 31, 2012 was approximately $152,000 and $32,000, respectively.  Accumulated depreciation on capital lease equipment was approximately $6,000 and $8,000 as of September 30, 2013 and December 31, 2012, respectively.

NOTE_PAYABLE_AND_DEBT_ISSUANCE

NOTE PAYABLE AND DEBT ISSUANCE COSTS	9 Months Ended
	Sep. 30, 2013
NOTE PAYABLE AND DEBT ISSUANCE COSTS [Abstract]	'
NOTE PAYABLE AND DEBT ISSUANCE COSTS	'
	4. NOTE PAYABLE AND DEBT ISSUANCE COSTS
	Note payable consists of the Company's loan agreement with HC Royalty, as lender, under which the Company agreed to borrow $50.0 million in two $25.0 million tranches.  The Company drew down the first tranche in the amount of $25.0 million in December 2012 and the second tranche in May 2013. With respect to the first $25.0 million tranche, for each calendar year (prorated for any portion thereof), the loan bears a royalty rate of 6.25% of the first $25.0 million of PROCYSBI and future approved product net revenues for such calendar year, 3.0% of the PROCYSBI and future approved product net revenues for such calendar year in excess of $25.0 million and below $50.0 million, and 1.0% of the PROCYSBI and future approved product net revenues for such calendar year in excess of $50.0 million, payable quarterly. With respect to the second $25.0 million tranche, for each calendar year (prorated for any portion thereof), the loan bears a royalty rate of 6.0% of the first $25.0 million of PROCYSBI and future approved product net revenues for such calendar year, 3.0% of the PROCYSBI and future approved product net revenues for such calendar year in excess of $25.0 million and below $50.0 million, and 1.0% of the PROCYSBI and future approved product net revenues for such calendar year in excess of $50.0 million, payable quarterly.
	The Company received marketing approval of PROCYSBI from the FDA on April 30, 2013 and commenced shipment of PROCYSBI during June 2013, and as a result, royalties became payable to HC Royalty based upon net revenues of PROCYSBI. Interest expense on the loan for the three and nine months ended September 30, 2013 was approximately $2.3 million and $4.1 million, respectively. As of September 30, 2013, the Company's note payable balance was $50.0 million and accrued royalty interest was $0.8 million.
	The loan and the Company's obligation to make any payments shall terminate immediately when all payments received by HC Royalty aggregate to $97.5 million. If, by December 20, 2014, net revenues for the immediately preceding four fiscal quarters exceed $100.0 million, then the loan and the Company's obligation to make any payments shall terminate immediately when all payments received by HC Royalty from the Company aggregate to $90.0 million.
	To secure the performance of its obligations under the HC Royalty Loan, the Company granted a security interest to HC Royalty in substantially all of its assets, the assets of its subsidiaries and a pledge of stock of certain of its domestic subsidiaries. The Company’s failure to comply with the terms of the HC Royalty Loan agreement and related documents, the occurrence of a change of control of the Company or the occurrence of an uncured material adverse effect on the Company, or the occurrence of certain other specified events, could result in an event of default under the HC Royalty Loan agreement that, if not cured or waived, could result in the acceleration of the payment of all of its indebtedness to HC Royalty and interest thereon. Under the terms of the security agreement, in an event of default, the lender could potentially take possession of, foreclose on, sell, assign or grant a license to use, the Company’s pledged collateral and assign and transfer the pledged stock of certain of its subsidiaries.

CAPITAL_STRUCTURE

CAPITAL STRUCTURE	9 Months Ended
	Sep. 30, 2013
CAPITAL STRUCTURE [Abstract]	'
CAPITAL STRUCTURE	'
	5. CAPITAL STRUCTURE
	As of September 30, 2013 and December 31, 2012, there were 61,142,756 and 52,424,649 shares, respectively, of the Company's common stock issued and outstanding.
	Common Stock Issuances under Stock Option Plans
	The Company received approximately $1.5 million from the exercise of stock options for the three- and nine-month periods ended September 30, 2013, resulting in the issuance of 370,352 shares and 378,366 shares, respectively, of common stock.
	Common Stock Issuance under At-The-Market Sales Agreement
	On April 30, 2012, the Company entered into a Sales Agreement with Cowen and Company, LLC ("Cowen"), under which the Company could, at its discretion, sell its common stock with a sales value of up to a maximum of $40.0 million through offerings deemed to be "at-the-market" ("ATM") on the NASDAQ Stock Market.  The Company pays Cowen as the sole sales agent a commission of 3.0% of the gross sales price for any sales made under the ATM.  The common stock is sold at prevailing market prices at the time of the sale of common stock, and, as a result, prices will vary.
	On July 3, 2013, the Company and Cowen amended and restated the Sales Agreement (the "Amended and Restated Sales Agreement") to increase the aggregate gross sales proceeds that may be raised to $100,000,000, of which approximately $37.1 million was previously sold pursuant to the original Sales Agreement dated April 30, 2012.
	Sales in the ATM offerings are being made pursuant to the prospectus supplement dated April 30, 2012, as amended by Amendment No. 2 dated July 3, 2013, which supplements the Company's prospectus dated February 3, 2012, filed as part of the shelf registration statement that was declared effective by the Securities and Exchange Commission ("SEC") on February 3, 2012.  Cumulatively through September 30, 2013, the Company sold 7,599,474 shares under the ATM offerings at a weighted-average selling price of $7.08 per share for net proceeds of approximately $52.1 million.
	Common Stock Warrants
	For the three- and nine-month periods ended September 30, 2013, the Company received approximately $3.1 million and $9.8 million, respectively, from the exercise of warrants in exchange for the issuance of 1,067,445 shares and 3,400,725 shares, respectively, of the Company's common stock.
	The table reflects the number of common stock warrants outstanding as of September 30, 2013:
	(In thousands, except per share amounts)	Number of shares			Exercise			Expiration date
		exercisable			price
	Issued in connection with Encode merger		233		$	2.87		12/13/15
	Issued to placement agents in August 2009		65		$	1.5		7/31/14
	TorreyPines warrants assumed in 2009 Merger		4		$	157.08		9/26/15
	Issued to registered direct investors in Dec. 2009		75		$	2.45		12/22/14
	Issued to private placement investors in Aug. 2010		670		$	3.075		8/12/15
	Issued to placement agent in Aug. 2010		98		$	3.075		8/12/15
	Total warrants outstanding		1,145		$	3.37	*
	*   Weighted-average exercise price
	The warrants issued by the Company in the August 2010 private placement and the December 2009 equity financing contain a conditional obligation that may require the Company to transfer assets to repurchase the warrants upon the occurrence of potential future events.  A financial instrument that may require the issuer to settle the obligation by transferring assets is classified as a liability.  Therefore, the Company has classified the warrants from both financings as liabilities and will mark them to fair value at each period end.
	A Black-Scholes option-pricing model was used to estimate the fair value of the warrant liabilities. These warrants were issued in the December 2009 and August 2010 equity financings using the following assumptions at September 30, 2013 and December 31, 2012:
		December 2009 equity							August 2010 private placement
		financing Series A							investors and placement agent
		September 30,			December 31,				September 30,			December 31,
		2013			2012				2013			2012
	Fair value (dollars in millions)	$	0.9		$	2.6			$	9.4		$	13.8
	Black-Scholes inputs:
	Stock price	$	14.92		$	5.85			$	14.92		$	5.85
	Exercise price	$	2.45		$	2.45			$	3.075		$	3.075
	Risk free interest rate		0.21	%		0.25	%			0.29	%		0.31	%
	Volatility		95	%		100	%			95	%		112	%
	Expected term (years)		1.25			2				1.75			2.5
	Dividend		0			0				0			0
	The Company recorded a loss of approximately $6.0 million and a gain of approximately $1.9 million for the three months ended September 30, 2013 and August 31, 2012, respectively, and a loss of approximately $12.0 million and a gain of approximately $1.0 million for the nine months ended September 30, 2013 and August 31, 2012, respectively, in its condensed consolidated statements of operations and comprehensive loss from changes in the fair values of warrants.
	Below is the activity of the warrant liabilities for the nine months ended September 30, 2013 and August 31, 2012:
		For the nine months ended
	(In millions)	September 30,			August 31,
		2013			2012
	Fair value of December 2009 direct offering warrants (including placement agent warrants) at beginning of the nine-month periods ended September 30, 2013 and August 31, 2012	$	2.6		$	6.7
	December 2009 warrants exercised		(4.2	)		(4.5	)
	Adjustment to fair value of common stock warrants		2.5			0.7
	December 2009 direct offering common stock warrant liability at fair value at September 30, 2013 and August 31, 2012		0.9			2.9
	Fair value of August 2010 private placement warrants (including broker warrants) at beginning of the nine-month periods ended September 30, 2013 and August 31, 2012		13.8			18.7
	August 2010 warrants exercised		(13.9	)		(2.7	)
	Adjustment to fair value of common stock warrants		9.5			(1.6	)
	August 2010 private placement common stock warrant liability at fair value at September 30, 2013 and August 31, 2012		9.4			14.4
	Total warrant liability at September 30, 2013 and August 31, 2012, respectively	$	10.3		$	17.3
	As discussed above, the Company uses the Black-Scholes option pricing model as its method of valuation for warrants that are subject to warrant liability accounting.  The determination of the fair value as of the reporting date is affected by Raptor's stock price as well as assumptions regarding a number of highly complex and subjective variables which could provide differing variables.  These variables include, but are not limited to, expected stock price volatility over the term of the security and risk-free interest rate.  In addition, the Black-Scholes option pricing model requires the input of an expected life for the securities which the Company has estimated based upon the stage of its development.  The fair value of the warrant liability is revalued each balance sheet date utilizing Black-Scholes valuation model computations with the decrease or increase in fair value being reported in the Condensed Consolidated Statement of Comprehensive Loss as other income or expense, respectively.  The Company's reported net loss was approximately $57.3 million for the nine months ended September 30, 2013.  If the Company's September 30, 2013 closing stock price had been 10% lower, its net loss would have been approximately $1.2 million lower.  If the Company's September 30, 2013 closing stock price had been 10% higher, its net loss would have been approximately $1.2 million higher.  If the Company's September 30, 2013 volatility assumption had been 10% lower, its net loss would have been approximately $0.1 million lower.  If the Company's September 30, 2013 volatility assumption had been 10% higher, its net loss would have been approximately $0.1 million higher.

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	9 Months Ended
	Sep. 30, 2013
ACCRUED LIABILITIES [Abstract]	'
ACCRUED LIABILITIES	'
	6. ACCRUED LIABILITIES
	Accrued liabilities consisted of:
		September 30,		December 31,
	(In thousands)	2013		2012
	Clinical trials and related costs	$	2,022	$	641
	Employee bonuses and commissions		1,756		502
	Commercial and administrative consulting		1,007		167
	Salaries and employee benefits		1,106		742
	Professional fees		815		67
	Interest expense on loan		809		0
	Revenue deductions		783		0
	Manufacturing costs		533		0
	Royalties		363		0
	Other		66		31
	Total accrued liabilities	$	9,260	$	2,150

STOCK_OPTION_PLANS

STOCK OPTION PLANS	9 Months Ended
	Sep. 30, 2013
STOCK OPTION PLANS [Abstract]	'
STOCK OPTION PLANS	'
	7. STOCK OPTION PLANS
	Stock-based compensation expense was based on the Black-Scholes option-pricing model assuming the following:
	Period*	Risk-free			Expected life of		Annual
		interest rate			stock option		volatility
	Quarter ended August 31, 2012		0.68	%	5 years			124.9	%
	Quarter ended September 30, 2013		1.51	%	5 years			67.18	%
	* Dividend rate is 0% for all periods presented.
	If factors change and different assumptions are employed in the application of ASC 718, the compensation expense recorded in future periods may differ significantly from what was recorded in the current period.
	A summary of the activity in the 2010 Equity Incentive Plan, as amended  (the "Plan"),  the 2006 Equity Compensation Plan, as amended, and the Company's other stock option plans, is as follows:
	(In thousands, except per share amounts)	Option				Weighted-				Exercisable		Weighted-
		shares				average						average fair
						exercise price						value of options
												granted
	Outstanding at December 31, 2012		7,791			$	5.79				3,494	$	3.48
	Granted		130				5.39				0		3.04
	Exercised		(8	)			0.85				0		0.62
	Canceled		(28	)			13.94				0		4.25
	Outstanding at March 31, 2013		7,885				5.76				4,031		3.47
	Granted		478				6.58				0		4.01
	Exercised		0				0				0		0
	Canceled		(27	)			20.7				0		4.73
	Outstanding at June 30, 2013		8,336				5.76				4,525		3.55
	Granted		317				11.06				0		5.32
	Exercised		(370	)			4.07				0		3.27
	Canceled		(53	)			38.14				0		0
	Outstanding at September 30, 2013		8,230				5.83				4,653		3.71
	At September 30, 2013, the total unrecognized compensation cost was approximately $14.0 million.  The weighted-average period over which it is expected to be recognized is approximately 3 years.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	8.  COMMITMENTS AND CONTINGENCIES
	The Company maintains several contracts with suppliers, contract manufacturers, research organizations, clinical organizations, drug labelers and distributors and clinical sites, primarily to assist with clinical research and clinical and commercial manufacturing and distribution of PROCYSBI and clinical manufacturing of drug product for the Company's HD and NAFLD clinical collaborations.  With the exception of the items disclosed below and updates as noted under Note 4 – Notes Payable and Debt Issuance Costs, the Company's contractual obligations did not change materially during the quarter ended September 30, 2013 compared to those disclosed as of December 31, 2012.
	On April 25, 2013, the Company executed a seven-year lease for a facility in Novato, California which it moved into at the end of June 2013 to accommodate personnel growth.  For the period June 2013 through May 2014, the Company is obligated to make lease payments of $19,460 per month.  On June 10, 2013, the Company amended the lease to add space to accommodate its research laboratory.  The Company is obligated to make additional lease payments of $1,870 per month for the period June 2013 through May 2014 under this amendment.  The Company plans to move to an adjacent facility when it becomes available in 2014.  Rental expense for the larger adjacent facility will be higher than the rental expense for the current facility.

DESCRIPTION_OF_BUSINESS_AND_SI1

DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Change in Fiscal Year End	'
	Change in Fiscal Year End
	In December 2012, Raptor's board of directors approved a change in the Company's fiscal year end from August 31 to December 31, effective on December 31, 2012.  The accompanying condensed consolidated financial statements cover the period from January 1, 2013 through September 30, 2013, representing the first nine months of Raptor's recently adopted fiscal year.  The prior year's comparable nine-month period covers December 1, 2011 through August 31, 2012, which is reported on the basis of Raptor's previous fiscal year end.  As a result of the change in Raptor's fiscal year end, the quarterly periods of Raptor's newly adopted fiscal year do not coincide with the historical quarterly periods that Raptor had previously reported.
Basis of Presentation	'
	Basis of Presentation
	The accompanying condensed consolidated financial statements reflect the results of operations of Raptor and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).  Certain information and footnotes have been condensed or omitted pursuant to such rules and regulations.  The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments (including normal recurring adjustments) considered necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. The condensed consolidated balance sheet as of December 31, 2012 has been derived from the Company’s audited financial statements as of such date, but does not include all disclosures required by GAAP. This Form 10-Q/A should be read in conjunction with the audited financial statements and accompanying notes in the Company's Transition Report on Form 10-KT/A for the four-month period ended December 31, 2012, as amended.
	The Company's condensed consolidated financial statements include the accounts of the Company's direct and indirect wholly owned subsidiaries, Raptor Pharmaceuticals Inc., formerly known as Raptor Therapeutics Inc. which merged with Raptor Discoveries Inc. in December 2012 prior to changing its name and Raptor European Products, LLC, such subsidiaries incorporated in Delaware on August 1, 2007, and February 14, 2012, respectively, and Raptor Pharmaceuticals Europe B.V. (domiciled in the Netherlands and formed on December 15, 2009), Raptor Pharmaceuticals France SAS (incorporated in France on October 30, 2012), Raptor Pharmaceuticals Germany GmbH (formed on September 28, 2013 and incorporated in Germany as a German company with limited liability on October 15, 2013) and RPTP European Holdings C.V. (located in the Grand Caymans and formed on February 16, 2012).  All intercompany accounts have been eliminated.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Revenue Recognition and Accounts Recievable	'
	Revenue Recognition and Accounts Receivable
	The Company recognizes revenue in accordance with the FASB ASC 605, Revenue Recognition, when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed; the price is fixed or determinable and collectability is reasonably assured.  The Company determines that persuasive evidence of an arrangement exists based on written contracts that define the terms of the arrangements.  Pursuant to the contract terms, the Company determines when title to products and associated risk of loss has passed onto the customer.  The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment.  The Company assesses collectability based primarily on the customer's payment history and creditworthiness.
	PROCYSBI is currently only available for distribution from the Company's U.S. specialty pharmacy partner, Accredo Health Group, Inc. ("Accredo"), which is currently the Company’s only customer and ships directly to patients.  PROCYSBI is not available in retail pharmacies.  Prior authorization of coverage level by patients' private insurance plans, our patient assistance program ("PAP") or government payors is a prerequisite to the shipment of PROCYSBI to patients.  Revenue is recognized once the product has been shipped by the specialty pharmacy to patients because the Company is unable to reasonably estimate the third-party payor mix and resulting rebates based on its lack of sufficient historical data.  Billings to the Company's distributor in advance of product shipment and delivery by the specialty pharmacy to patients are recorded as deferred revenues by the Company until such shipments to patients occur.
	The Company records revenue net of expected returns, discounts, distributor fees, rebates, including those paid to U.S. government agencies.  Allowances are recorded as a reduction of revenue at the time product sales are recognized.  Allowances for government rebates and discounts are established based on the actual payor information, which is known at the time of shipment to patients, and the government-mandated discounts applicable to government-funded programs.  The allowances are adjusted to reflect known changes in the factors that may impact such allowances in the quarter the changes are known.
	Trade accounts receivable are recorded net of product sales allowances for prompt-payment discounts and chargebacks.  Estimates for chargebacks and prompt-payment discounts are based on contractual terms and the Company's expectations regarding the utilization rates.
Inventories and Cost of Sales	'
	Inventories and Cost of Sales
	Inventories are stated at the lower of cost or market price, with cost determined on a first-in, first-out basis.  Inventories are reviewed periodically to identify slow-moving inventory based on sales activity, both projected and historical, as well as product shelf-life.   Prior to the approval of PROCYSBI by the FDA on April 30 2013, the Company recorded the purchase of raw materials and the manufacturing costs relating to PROCYSBI as research and development expense.  Subsequent to approval, the Company began capitalizing these costs as commercial inventory.  As of September 30, 2013, net inventories were approximately $2.2 million, which consisted of $1.8 million of raw materials, $0.3 million of work-in-process and $0.5 million of finished goods, offset by a reserve allowance of $0.4 million.  Upon launching PROCYSBI in mid-June 2013, the Company began recognizing cost of sales.  During the second quarter ended June 30, 2013, the Company recorded a $0.4 million reserve as cost of sales expense representing commercial inventory that was capitalized subsequent to FDA approval but written off due to an unanticipated minor change in the finished product presentation.  No write-off occurred in the third quarter.  Cost of sales includes the cost of inventory sold and reserved, manufacturing and supply chain costs, product shipping and handling costs, amortization of licensing approval milestone payments and licensing royalties payable to the University of California, San Diego ("UCSD").
Comprehensive Loss	'
	Comprehensive Loss
	The components of comprehensive loss include net loss and foreign currency translation adjustments.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents.  The Company maintains cash and cash equivalents, which consist principally of money market funds with high credit quality financial institutions.  Such amounts exceed Federal Deposit Insurance Corporation insurance limits.  Restricted cash represents compensating balances required by the Company's U.S. bank as collateral for credit cards.
Short-term Investments	'
	Short-term Investments
	The Company typically invests in short-term investments in high credit-quality funds in order to obtain higher yields on its cash available for investment.  The Company had no short-term investments at September 30, 2013 compared to approximately $22.1 million at December 31, 2012.  The Company regularly evaluates its short-term investment fund options and in the future may invest a portion of its cash and cash equivalents balance ($88.3 million as of September 30, 2013) in higher credit-quality and higher-yielding short-term investment funds.
	Such investments are not insured by the Federal Deposit Insurance Corporation.  The Company completed an evaluation of its investments and determined that it did not have any other-than-temporary impairments as of September 30, 2013 or December 31, 2012.
Accounts Receivable	'
	Accounts Receivable
	Trade accounts receivable are recorded net of product sales allowances for prompt-payment discounts, chargebacks and doubtful accounts.  Estimates for chargebacks and prompt-payment discounts are based on contractual terms and the Company's expectations regarding the utilization rates.  As of September 30, 2013, the Accredo Health Group, Inc. ("Accredo"), Raptor's exclusive distributor in the U.S., is the Company's only significant customer for PROCYSBI in the U.S.  Raptor's distributor in the EU will be the Almac Group, Ltd. for the commercial launch in the EU anticipated to occur in the first half of 2014.
Functional Currency	'
	Functional Currency
	The Company's consolidated functional currency is the U.S. dollar.  Raptor Pharmaceuticals Europe B.V. ("BV"), Raptor Pharmaceuticals France SAS ("SAS") and RPTP European Holdings C.V. ("CV"), the Company's European subsidiaries and Cayman-based subsidiary, respectively, use the European Euro as their functional currency.  At each quarter end, each foreign subsidiary's balance sheets are translated into U.S. dollars based upon the quarter-end exchange rate, while their statements of operations and comprehensive loss are translated into U.S. dollars based upon an average exchange rate.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of certain of the Company's financial instruments including cash equivalents, restricted cash, accounts payable, accrued liabilities, note payable and capital lease liability approximate fair value due either to length of maturity or interest rates that approximate prevailing market rates. The warrant liability is carried at fair value which is determined using the Black-Scholes option valuation model at the end of each reporting period.
	The Company uses a fair value approach to value certain assets and liabilities.  Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The hierarchy consists of three levels:
		·	Level one - Quoted market prices in active markets for identical assets or liabilities;
		·	Level two - Inputs other than level one inputs that are either directly or indirectly observable; and
		·	Level three - Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.  Assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 are summarized as follows:
	(In thousands)
	Assets		Level 1		Level 2		Level 3		September 30,
									2013
	Fair value of cash equivalents		$	71,434	$	0	$	0	$	71,434
	Total		$	71,434	$	0	$	0	$	71,434
	Liabilities
	Fair value of common stock warrants		$	0	$	0	$	10,339	$	10,339
	Total		$	0	$	0	$	10,339	$	10,339
	Assets		Level 1		Level 2		Level 3		31-Dec-12
	Fair value of cash equivalents		$	35,069	$	0	$	0	$	35,069
	Short-term investments			22,096		0		0		22,096
	Total		$	57,165	$	0	$	0	$	57,165
	Liabilities
	Fair value of common stock warrants		$	0	$	0	$	16,405	$	16,405
	Total		$	0	$	0	$	16,405	$	16,405
	See Note 5 for further discussion of the calculation of the fair value of the common stock warrant liability.
Intangible Assets	'
	Intangible Assets
	Intangible assets primarily include the intellectual property and other rights relating to DR Cysteamine (developed as PROCYSBI/RP103), and an out-license acquired in a 2009 Merger.  The other intangible assets related to PROCYSBI/RP103 are amortized using the straight-line method over the estimated useful life of 20 years, which is the life of the intellectual property patents.  The 20-year estimated useful life is also based upon the typical development, approval, marketing and life cycle management timelines of pharmaceutical drug products.   Intangible assets related to the out-license are amortized using the straight-line method over the estimated useful life of 16 years, which is the life of the intellectual property patents.
Fixed Assets	'
	Fixed Assets
	Fixed assets, which mainly consist of leasehold improvements, furniture and fixtures, lab equipment, computer hardware and software and capital lease equipment, are stated at cost.  Depreciation is computed using the straight-line method over the related estimated useful lives, except for leasehold improvements and capital lease equipment, which are depreciated over the shorter of the useful life of the asset or the lease term. Significant additions and improvements that have useful lives estimated at greater than one year are capitalized, while repairs and maintenance are charged to expense as incurred.
Impairment of Goodwill and Long-Lived Assets	'
	Impairment of Goodwill and Long-Lived Assets
	Goodwill represents the excess of purchase price over the fair value of tangible and identified intangible assets of businesses acquired. Goodwill is not amortized, but is evaluated for impairment on an annual basis or more often when impairment indicators are present. When an impairment analysis is performed, if deemed necessary, a write-down in valuation is recorded.
	The Company has one reporting unit. Therefore, the Company’s consolidated net assets, including existing goodwill and other intangible assets, are considered to be the carrying value of the reporting unit. If the carrying value of the reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the analysis, in which the implied fair value of the goodwill is compared to its carrying value to determine the impairment charge, if any. If the estimated fair value of the reporting unit exceeds the carrying value of the reporting unit, goodwill is not impaired and no further analysis is required.
	The Company makes judgments about the recoverability of purchased intangible assets with finite lives and other long-lived assets whenever events or changes in circumstances indicate that impairment may exist. Recoverability of purchased intangible assets with finite lives and other long-lived assets is measured by comparing the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. Impairment, if any, is measured as the amount by which the carrying value exceeds the fair value of the impaired asset.
Accrued Liabilities	'
	Accrued Liabilities
	Accrued liabilities include estimates of certain expenses for which the Company has not yet been invoiced and which requires management's judgment in determining appropriate expenses to accrue.   Although the Company believes its accrued liabilities reflect the best information available to it, the Company's actual expenses could differ from its estimates.
Common Stock Warrant Liabilities	'
	Common Stock Warrant Liabilities
	The Company issued warrants that contain conditional obligations that may require the Company to transfer cash to settle the warrants upon the occurrence of certain fundamental transactions. Therefore, the Company has classified the warrants as liabilities.  The Company re-measures the liability at the end of every reporting period with the change in value reported in the Company’s consolidated statements of operations and comprehensive loss.  At the exercise date, the fair values of these warrants are re-measured and reclassified to equity.
Deferred Offering Costs	'
	Deferred Offering Costs
	Deferred offering costs represent expenses incurred to raise equity capital related to financing transactions which have not yet been completed as of the balance sheet dates.
Note Payable and Debt Issuance Costs	'
	Note Payable and Debt Issuance Costs
	Note payable consists of the Company's loan agreement with HealthCare Royalty Partners II, L.P. ("HC Royalty"), as lender, under which Raptor agreed to borrow $50.0 million in two $25.0 million tranches.  The Company received the first tranche in December 2012 and the second tranche in May 2013.  The loan bears interest at an annual fixed rate of 10.75% of outstanding principal and includes a synthetic royalty component based on net product sales, including PROCYSBI, in a calendar year.  The fixed and royalty interest are recognized as interest expense as incurred. Debt issuance costs, which were capitalized and included in other long-term assets, are being amortized over the life of the loan using the interest method.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs are charged to expense as incurred. Research and development expenses include medical, clinical, regulatory and scientists' salaries and benefits, lab collaborations, preclinical studies, clinical trials, clinical trial materials, commercial drug manufacturing expenses prior to obtaining marketing approval, regulatory and clinical consultants, lab supplies, lab services, lab equipment maintenance and small equipment purchased to support the research laboratory, amortization of intangible assets and allocated human resources and facilities expenses.
Income Taxes	'
	Income Taxes
	Income taxes are recorded under the liability method, under which deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.  Based on the weight of available evidence, including cumulative losses since inception and expected future losses, the Company has determined that it is more likely than not that the deferred tax asset amount will not be realized and therefore a full valuation allowance has been provided on the Company’s net deferred tax assets.
	The Company identifies uncertain tax positions and discloses any potential tax liability on its financial statements.  The Company recognizes interest and/or penalties related to income tax matters as a component of income tax expense.
	As of September 30, 2013, there were no liabilities recorded related to uncertain tax positions and no accrued interest or penalties related to uncertain tax positions.
	The Company files U.S. Federal, California, various other state income and other tax returns and various foreign country income tax returns.  The Company is currently not subject to any income tax examinations.  Due to the Company's net operating losses, generally all tax years remain open.
Net Loss per Share	'
	Net Loss per Share
	Net loss per share is calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period.  Diluted net income per share is calculated by dividing net income by the weighted-average shares of common stock outstanding and potential shares of common stock during the period.  For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net loss per share as their effect is anti-dilutive.  Potentially dilutive securities include:
			Nine months ended
	(In thousands)		30-Sep-13		31-Aug-12
	Warrants to purchase common stock			1,145		5,188
	Options to purchase common stock			8,230		6,125
	Total potentially dilutive securities			9,375		11,313
	Net loss per share, basic and diluted, was $(0.29) and $(0.21) for the three months ended September 30, 2013 and August 31, 2012, respectively, and $(1.01) and $(0.56) for the nine months ended September 30, 2013 and August 31, 2012, respectively.
Stock Option Plan	'
	Stock Option Plan
	Compensation cost related to the Company’s stock option plans is measured at the grant date based on the fair value of the equity instruments awarded and is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award, or the requisite service period, which is usually the vesting period. The Company recognizes expense associated with stock options issued to third parties, including consultants, based upon the fair values of such awards on the dates the awards vest.
Reclassifications	'
	Reclassifications
	Certain amounts previously reported under specific financial statement captions have been reclassified to be consistent with the current period presentation.

DESCRIPTION_OF_BUSINESS_AND_SI2

DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2013
DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Assets and liabilities measured at fair value on a recurring basis	'
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.  Assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 are summarized as follows:
	(In thousands)
	Assets	Level 1		Level 2		Level 3		September 30,
								2013
	Fair value of cash equivalents	$	71,434	$	0	$	0	$	71,434
	Total	$	71,434	$	0	$	0	$	71,434
	Liabilities
	Fair value of common stock warrants	$	0	$	0	$	10,339	$	10,339
	Total	$	0	$	0	$	10,339	$	10,339
	Assets	Level 1		Level 2		Level 3		31-Dec-12
	Fair value of cash equivalents	$	35,069	$	0	$	0	$	35,069
	Short-term investments		22,096		0		0		22,096
	Total	$	57,165	$	0	$	0	$	57,165
	Liabilities
	Fair value of common stock warrants	$	0	$	0	$	16,405	$	16,405
	Total	$	0	$	0	$	16,405	$	16,405
Potentially dilutive securities	'
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net loss per share as their effect is anti-dilutive.  Potentially dilutive securities include:
		Nine months ended
	(In thousands)	30-Sep-13		31-Aug-12
	Warrants to purchase common stock		1,145		5,188
	Options to purchase common stock		8,230		6,125
	Total potentially dilutive securities		9,375		11,313

INTANGIBLE_ASSETS_AND_GOODWILL1

INTANGIBLE ASSETS AND GOODWILL (Tables)	9 Months Ended
	Sep. 30, 2013
INTANGIBLE ASSETS AND GOODWILL [Abstract]	'
Summary of intangibles acquired	'
	A summary of intangible assets acquired is as follows:
	(In thousands)	30-Sep-13			31-Dec-12
	Intangible asset (IP license for PROCYSBI/RP103) related to the Encode merger	$	2,620		$	2,620
	Intangible assets (out-license) related to the 2009 Merger		240			240
	Intangible assets (UCSD license FDA and EC approval milestones)		1,250			0
	Total intangible assets		4,110			2,860
	Less accumulated amortization		(838	)		(704	)
	Intangible assets, net	$	3,272		$	2,156
Actual and estimated amortization expense for intangible assets	'
	Amortization expense for intangible assets for the periods indicated is expected to be as follows:
	Year ending December 31, (In thousands)	Amortization
		expense
	2013  (remaining 3 months)	$	194
	2014		238
	2015		238
	2016		238
	2017		238

FIXED_ASSETS_Tables

FIXED ASSETS (Tables)	9 Months Ended
	Sep. 30, 2013
FIXED ASSETS [Abstract]	'
FIXED ASSETS	'
	Fixed assets consisted of:
		September 30,			December 31,
	Category (In thousands)	2013			2012			Estimated useful lives
	Leasehold improvements	$	0		$	146		Shorter of life of asset or lease term
	Office furniture		497			35		7 years
	Laboratory equipment		902			593		5 years
	Computer hardware and software		426			204		3 years
	Capital lease equipment		68			27		Shorter of life of asset or lease term
	Total at cost		1,893			1,005
	Less: accumulated depreciation		(584	)		(589	)
	Total fixed assets, net	$	1,309		$	416

CAPITAL_STRUCTURE_Tables

CAPITAL STRUCTURE (Tables)	9 Months Ended
	Sep. 30, 2013
CAPITAL STRUCTURE [Abstract]	'
Number of outstanding common stock warrants	'
	The table reflects the number of common stock warrants outstanding as of September 30, 2013:
	(In thousands, except per share amounts)	Number of shares			Exercise			Expiration date
		exercisable			price
	Issued in connection with Encode merger		233		$	2.87		12/13/15
	Issued to placement agents in August 2009		65		$	1.5		7/31/14
	TorreyPines warrants assumed in 2009 Merger		4		$	157.08		9/26/15
	Issued to registered direct investors in Dec. 2009		75		$	2.45		12/22/14
	Issued to private placement investors in Aug. 2010		670		$	3.075		8/12/15
	Issued to placement agent in Aug. 2010		98		$	3.075		8/12/15
	Total warrants outstanding		1,145		$	3.37	*
	*   Weighted-average exercise price
Assumptions for fair value of the warrants	'
	These warrants were issued in the December 2009 and August 2010 equity financings using the following assumptions at September 30, 2013 and December 31, 2012:
		December 2009 equity							August 2010 private placement
		financing Series A							investors and placement agent
		September 30,			December 31,				September 30,			December 31,
		2013			2012				2013			2012
	Fair value (dollars in millions)	$	0.9		$	2.6			$	9.4		$	13.8
	Black-Scholes inputs:
	Stock price	$	14.92		$	5.85			$	14.92		$	5.85
	Exercise price	$	2.45		$	2.45			$	3.075		$	3.075
	Risk free interest rate		0.21	%		0.25	%			0.29	%		0.31	%
	Volatility		95	%		100	%			95	%		112	%
	Expected term (years)		1.25			2				1.75			2.5
	Dividend		0			0				0			0
Activity of the warrant liabilities	'
	Below is the activity of the warrant liabilities for the nine months ended September 30, 2013 and August 31, 2012:
		For the nine months ended
	(In millions)	September 30,			August 31,
		2013			2012
	Fair value of December 2009 direct offering warrants (including placement agent warrants) at beginning of the nine-month periods ended September 30, 2013 and August 31, 2012	$	2.6		$	6.7
	December 2009 warrants exercised		(4.2	)		(4.5	)
	Adjustment to fair value of common stock warrants		2.5			0.7
	December 2009 direct offering common stock warrant liability at fair value at September 30, 2013 and August 31, 2012		0.9			2.9
	Fair value of August 2010 private placement warrants (including broker warrants) at beginning of the nine-month periods ended September 30, 2013 and August 31, 2012		13.8			18.7
	August 2010 warrants exercised		(13.9	)		(2.7	)
	Adjustment to fair value of common stock warrants		9.5			(1.6	)
	August 2010 private placement common stock warrant liability at fair value at September 30, 2013 and August 31, 2012		9.4			14.4
	Total warrant liability at September 30, 2013 and August 31, 2012, respectively	$	10.3		$	17.3

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2013
ACCRUED LIABILITIES [Abstract]	'
Accrued liabilities	'
	Accrued liabilities consisted of:
		September 30,		December 31,
	(In thousands)	2013		2012
	Clinical trials and related costs	$	2,022	$	641
	Employee bonuses and commissions		1,756		502
	Commercial and administrative consulting		1,007		167
	Salaries and employee benefits		1,106		742
	Professional fees		815		67
	Interest expense on loan		809		0
	Revenue deductions		783		0
	Manufacturing costs		533		0
	Royalties		363		0
	Other		66		31
	Total accrued liabilities	$	9,260	$	2,150

STOCK_OPTION_PLANS_Tables

STOCK OPTION PLANS (Tables)	9 Months Ended
	Sep. 30, 2013
STOCK OPTION PLANS [Abstract]	'
Black-Scholes option-pricing model assumptions	'
	Stock-based compensation expense was based on the Black-Scholes option-pricing model assuming the following:
	Period*	Risk-free			Expected life of		Annual
		interest rate			stock option		volatility
	Quarter ended August 31, 2012		0.68	%	5 years			124.9	%
	Quarter ended September 30, 2013		1.51	%	5 years			67.18	%
Summary of the activity in stock option plan	'
	A summary of the activity in the 2010 Equity Incentive Plan, as amended  (the "Plan"),  the 2006 Equity Compensation Plan, as amended, and the Company's other stock option plans, is as follows:
	(In thousands, except per share amounts)	Option				Weighted-				Exercisable		Weighted-
		shares				average						average fair
						exercise price						value of options
												granted
	Outstanding at December 31, 2012		7,791			$	5.79				3,494	$	3.48
	Granted		130				5.39				0		3.04
	Exercised		(8	)			0.85				0		0.62
	Canceled		(28	)			13.94				0		4.25
	Outstanding at March 31, 2013		7,885				5.76				4,031		3.47
	Granted		478				6.58				0		4.01
	Exercised		0				0				0		0
	Canceled		(27	)			20.7				0		4.73
	Outstanding at June 30, 2013		8,336				5.76				4,525		3.55
	Granted		317				11.06				0		5.32
	Exercised		(370	)			4.07				0		3.27
	Canceled		(53	)			38.14				0		0
	Outstanding at September 30, 2013		8,230				5.83				4,653		3.71

DESCRIPTION_OF_BUSINESS_AND_SI3

DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jun. 25, 2013	Sep. 30, 2013	Aug. 31, 2012	Sep. 30, 2013	Aug. 31, 2012	Apr. 30, 2013	Dec. 31, 2012
		Tranche		Tranche		Age
DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'	'	'	'	'	'	'
Minimum age of children for management of nephropathic cystinosis	'	'	'	'	'	6	'
Period of orphan drug exclusivity for PROCYSBI in U.S.	'7 years	'	'	'	'	'	'
Period of orphan drug exclusivity for PROCYSBI in EU	'10 years	'	'	'	'	'	'
Inventories and Cost of Sales [Abstract]	'	'	'	'	'	'	'
Net inventories	'	$2,218,000	'	$2,218,000	'	'	$0
Raw materials	'	1,800,000	'	1,800,000	'	'	'
Work-in-process	'	300,000	'	300,000	'	'	'
Finished goods	'	500,000	'	500,000	'	'	'
Reserve allowance	'	400,000	'	400,000	'	'	'
Cost of sales	'	425,000,000	'	'	'	'	'
Cash and Cash Equivalents [Abstract]	'	'	'	'	'	'	'
Maximum maturity period for investments considered as highly liquid investments	'	'	'	'3 months	'	'	'
Short-term Investments [Abstract]	'	'	'	'	'	'	'
Short-term investments	'	0	'	0	'	'	22,096,000
Liabilities	'	'	'	'	'	'	'
Fair value of common stock warrants	'	10,300,000	17,300,000	10,300,000	17,300,000	'	'
Fixed Assets [Abstract]	'	'	'	'	'	'	'
Useful life of significant additions and improvements in fixed assets for capitalization, minimum	'	'	'	'1 year	'	'	'
Note Payable and Debt Issuance Costs [Abstract]	'	'	'	'	'	'	'
Total amount of loan	'	50,000,000	'	50,000,000	'	'	'
Number of tranches in loan	'	2	'	2	'	'	'
Amount of loan per tranche	'	25,000,000	'	25,000,000	'	'	'
Annual fixed interest rate (in hundredths)	'	10.75%	'	10.75%	'	'	'
Income taxes [Abstract]	'	'	'	'	'	'	'
Accrued interest or penalties related to uncertain tax positions	'	0	'	0	'	'	'
Unrecognized tax benefits	'	0	'	0	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'
Total potentially dilutive securities (in shares)	'	'	'	9,375	11,313	'	'
Net loss per share, basic and diluted (in dollars per share)	'	($0.29)	($0.21)	($1.01)	($0.56)	'	'
Fair value assumptions used based on Black-Scholes option-pricing model [Abstract]	'	'	'	'	'	'	'
Risk-free interest rate (in hundredths)	'	'	'	1.51%	'	'	'
Expected life	'	'	'	'5 years	'	'	'
Volatility (in hundredths)	'	'	'	67.18%	'	'	'
Turnover rate (in hundredths)	'	'	'	2.50%	'	'	'
Dividend rate (in hundredths)	'	'	'	0.00%	'	'	'
Period over which current constant maturity treasury bill rates were reviewed	'	'	'	'5 years	'	'	'
Term of stock options issued	'	'	'	'10 years	'	'	'
Warrants to Purchase Common Stock [Member]	'	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'
Total potentially dilutive securities (in shares)	'	'	'	1,145	5,188	'	'
Options to Purchase Common Stock [Member]	'	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'
Total potentially dilutive securities (in shares)	'	'	'	8,230	6,125	'	'
IP license for PROCYSBI RP103 [Member]	'	'	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'
Estimated useful life of intangible assets	'	'	'	'20 years	'	'	'
Out license [Member]	'	'	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'
Estimated useful life of intangible assets	'	'	'	'16 years	'	'	'
Recurring [Member]	'	'	'	'	'	'	'
Assets	'	'	'	'	'	'	'
Fair value of cash equivalents	'	71,434,000	'	71,434,000	'	'	35,069,000
Short-term investments	'	'	'	'	'	'	22,096,000
Total	'	71,434,000	'	71,434,000	'	'	57,165,000
Liabilities	'	'	'	'	'	'	'
Fair value of common stock warrants	'	10,339,000	'	10,339,000	'	'	16,405,000
Total	'	10,339,000	'	10,339,000	'	'	16,405,000
Recurring [Member] | Level 1 [Member]	'	'	'	'	'	'	'
Assets	'	'	'	'	'	'	'
Fair value of cash equivalents	'	71,434,000	'	71,434,000	'	'	35,069,000
Short-term investments	'	'	'	'	'	'	22,096,000
Total	'	71,434,000	'	71,434,000	'	'	57,165,000
Liabilities	'	'	'	'	'	'	'
Fair value of common stock warrants	'	0	'	0	'	'	0
Total	'	0	'	0	'	'	0
Recurring [Member] | Level 2 [Member]	'	'	'	'	'	'	'
Assets	'	'	'	'	'	'	'
Fair value of cash equivalents	'	0	'	0	'	'	0
Short-term investments	'	'	'	'	'	'	0
Total	'	0	'	0	'	'	0
Liabilities	'	'	'	'	'	'	'
Fair value of common stock warrants	'	0	'	0	'	'	0
Total	'	0	'	0	'	'	0
Recurring [Member] | Level 3 [Member]	'	'	'	'	'	'	'
Assets	'	'	'	'	'	'	'
Fair value of cash equivalents	'	0	'	0	'	'	0
Short-term investments	'	'	'	'	'	'	0
Total	'	0	'	0	'	'	0
Liabilities	'	'	'	'	'	'	'
Fair value of common stock warrants	'	10,339,000	'	10,339,000	'	'	16,405,000
Total	'	$10,339,000	'	$10,339,000	'	'	$16,405,000

INTANGIBLE_ASSETS_AND_GOODWILL2

INTANGIBLE ASSETS AND GOODWILL (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Jun. 30, 2013

31-May-12

Sep. 30, 2013

Aug. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2009

Sep. 30, 2013

Dec. 31, 2012

Aug. 31, 2012

Dec. 31, 2009

IP license for PROCYSBI/RP103 [Member]

IP license for PROCYSBI/RP103 [Member]

Out license [Member]

Out license [Member]

Out license [Member]

UCSD license FDA approval milestone [Member]

UCSD license FDA approval milestone [Member]

Tezampanel/ NGX426 [Member]

Tezampanel/ NGX426 [Member]

Encode Pharmaceuticals, Inc. [Member]

Encode Pharmaceuticals, Inc. [Member]

2009 Merger [Member]

2009 Merger [Member]

2009 Merger [Member]

Encode Pharmaceuticals, Inc. [Member]

Encode Pharmaceuticals, Inc. [Member]

2009 Merger [Member]

2009 Merger [Member]

Summary of intangible assets [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total intangible assets

$4,110,000

'

'

$4,110,000

'

$2,860,000

$2,620,000

$2,620,000

$240,000

$240,000

$1,100,000

$1,250,000

$0

'

'

Less accumulated amortization

-838,000

'

'

-838,000

'

-704,000

'

'

'

'

'

'

'

'

'

Intangible assets, net

3,272,000

'

'

3,272,000

'

2,156,000

'

'

'

'

'

'

'

'

'

Intangible assets acquired in the merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

Intangible asset, fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

Impairment of assets charged to research and development expense

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

Amortization charged to research and development expense

47,000

'

37,000

134,000

109,000

'

'

'

'

'

'

'

'

'

'

Actual and estimated amortization expense for intangible assets [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2013

194,000

'

'

194,000

'

'

'

'

'

'

'

'

'

'

'

2014

238,000

'

'

238,000

'

'

'

'

'

'

'

'

'

'

'

2015

238,000

'

'

238,000

'

'

'

'

'

'

'

'

'

'

'

2016

238,000

'

'

238,000

'

'

'

'

'

'

'

'

'

'

'

2017

238,000

'

'

238,000

'

'

'

'

'

'

'

'

'

'

'

Licensing milestone payment capitalized

$750,000

$500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

FIXED_ASSETS_Details

FIXED ASSETS (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Aug. 31, 2012	Sep. 30, 2013	Aug. 31, 2012	Dec. 31, 2012
Fixed assets [Abstract]	'	'	'	'	'
Total at cost	$1,893,000	'	$1,893,000	'	$1,005,000
Less: accumulated depreciation	-584,000	'	-584,000	'	-589,000
Total fixed assets, net	1,309,000	'	1,309,000	'	416,000
Estimated useful lives [Abstract]	'	'	'	'	'
Depreciation expense	74,000	29,000	152,000	32,000	'
Leasehold Improvements [Member]	'	'	'	'	'
Fixed assets [Abstract]	'	'	'	'	'
Total at cost	0	'	0	'	146,000
Estimated useful lives [Abstract]	'	'	'	'	'
Estimated useful lives	'	'	'Shorter of life of asset or lease term	'	'
Office Furniture [Member]	'	'	'	'	'
Fixed assets [Abstract]	'	'	'	'	'
Total at cost	497,000	'	497,000	'	35,000
Estimated useful lives [Abstract]	'	'	'	'	'
Estimated useful lives	'	'	'7 years	'	'
Laboratory Equipment [Member]	'	'	'	'	'
Fixed assets [Abstract]	'	'	'	'	'
Total at cost	902,000	'	902,000	'	593,000
Estimated useful lives [Abstract]	'	'	'	'	'
Estimated useful lives	'	'	'5 years	'	'
Computer Hardware and Software [Member]	'	'	'	'	'
Fixed assets [Abstract]	'	'	'	'	'
Total at cost	426,000	'	426,000	'	204,000
Estimated useful lives [Abstract]	'	'	'	'	'
Estimated useful lives	'	'	'3 years	'	'
Capital Lease Equipment [Member]	'	'	'	'	'
Fixed assets [Abstract]	'	'	'	'	'
Total at cost	68,000	'	68,000	'	27,000
Less: accumulated depreciation	$6,000	'	$6,000	'	$8,000
Estimated useful lives [Abstract]	'	'	'	'	'
Estimated useful lives	'	'	'Shorter of life of asset or lease term	'	'

NOTE_PAYABLE_AND_DEBT_ISSUANCE1

NOTE PAYABLE AND DEBT ISSUANCE COSTS (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	21-May-13	Sep. 30, 2013
	Tranche		Loan Agreement with HC Royalty [Member]	Loan Agreement with HC Royalty [Member]	Loan Agreement with HC Royalty [Member]	Loan Agreement with HC Royalty [Member]	Loan Agreement with HC Royalty [Member]
			Tranche	First Tranche [Member]	First Tranche [Member]	Second Tranche [Member]	Second Tranche [Member]
			Quarter
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Total amount of loan	$50,000,000	'	$50,000,000	'	'	'	'
Number of tranches in loan	2	'	2	'	'	'	'
Amount of loan per tranche	25,000,000	'	25,000,000	'	'	'	'
Draw down on loan	'	'	'	25,000,000	'	25,000,000	'
Royalty rate of first threshold of PROCYSBI and future approved product net revenues for calendar year (in hundredths)	'	'	'	'	6.25%	'	6.00%
Amount of first threshold of PROCYSBI and future approved product net revenues for calendar year	'	'	'	'	25,000,000	'	25,000,000
Royalty rate of amount between first and second threshold of PROCYSBI and future approved product net revenues for calendar year (in hundredths)	'	'	'	'	3.00%	'	3.00%
Amount of second threshold of PROCYSBI and future approved product net revenues for calendar year	'	'	'	'	50,000,000	'	50,000,000
Royalty rate for amount in excess of second threshold of PROCYSBI and future approved product net revenues for calendar year (in hundredths)	'	'	'	'	1.00%	'	1.00%
Accrued royalties	'	'	800,000	'	'	'	'
Note payable outstanding	50,000,000	25,000,000	50,000,000	'	'	'	'
Total payment required to terminate loan obligation immediately	'	'	97,500,000	'	'	'	'
Number of fiscal quarters of net revenues included in total loan payment consideration	'	'	4	'	'	'	'
Threshold net revenues during specified period included in total loan payment consideration	'	'	100,000,000	'	'	'	'
Total payment required upon net revenues exceeding threshold during specified period to terminate loan obligation immediately	'	'	$90,000,000	'	'	'	'

CAPITAL_STRUCTURE_COMMON_STOCK

CAPITAL STRUCTURE, COMMON STOCK (Details) (USD $)	3 Months Ended	9 Months Ended		0 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Jul. 03, 2013	Sep. 30, 2013	Apr. 30, 2012
				Shares Issued under ATM Sales Agreement [Member]	Shares Issued under ATM Sales Agreement [Member]	Shares Issued under ATM Sales Agreement [Member]
Class of Stock [Line Items]	'	'	'	'	'	'
Common stock issued (in shares)	61,142,756	61,142,756	52,424,649	'	7,599,474	'
Common stock outstanding (in shares)	61,142,756	61,142,756	52,424,649	'	'	'
Exercises of stock options	$1,500,000	$1,516,000	'	'	'	'
Exercise of stock options (in shares)	370,352	378,366	'	'	'	'
Maximum amount of common stock under ATM sales agreement	'	'	'	100,000,000	'	40,000,000
Sales commission percentage for sales made under ATM (in hundredths)	'	'	'	'	3.00%	'
Total amount of common stock sold pursuant to original Sales Agreement	'	'	'	37,100,000	'	'
Weighted-average selling price of shares sold under the ATM offering (in dollars per share)	'	'	'	'	$7.08	'
Cumulative net proceeds from sale of shares	'	'	'	'	$52,100,000	'

CAPITAL_STRUCTURE_COMMON_STOCK1

CAPITAL STRUCTURE, COMMON STOCK WARRANTS (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Aug. 31, 2012

Sep. 30, 2013

Aug. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Aug. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Aug. 31, 2012

Dec. 31, 2012

Jun. 30, 2013

Issued in Connection with Encode Merger [Member]

Issued to Placement Agents in August 2009 [Member]

2009 Merger [Member]

Issued to Registered Direct Investors in Dec. 2009 [Member]

Issued to Private Placement Investors in Aug. 2010 [Member]

Issued to Placement Agent in Aug. 2010 [Member]

December 2009 Equity Financing, Series A [Member]

December 2009 Equity Financing, Series A [Member]

December 2009 Equity Financing, Series A [Member]

August 2010 Private Placement, Investors and Placement Agent [Member]

August 2010 Private Placement, Investors and Placement Agent [Member]

August 2010 Private Placement, Investors and Placement Agent [Member]

August 2010 Private Placement, Investors and Placement Agent [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the exercise of common stock warrants

$3,100,000

'

$9,809,000

$3,057,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of common stock warrants (in shares)

1,067,445

'

3,400,725

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrants outstanding [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares exercisable (in shares)

1,145,000

'

1,145,000

'

233,000

65,000

4,000

75,000

670,000

98,000

'

'

'

'

'

'

'

Exercise price (in dollars per share)

$3.37

[1]

'

$3.37

[1]

'

$2.87

$1.50

$157.08

[1]

$2.45

$3.08

$3.08

'

'

'

'

'

'

'

Expiration date

'

'

'

'

'12/13/2015

'7/31/2014

'9/26/2015

'12/22/2014

'8/12/2015

'8/12/2015

'

'

'

'

'

'

'

Assumptions to obtain the fair value of the warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value

'

'

'

'

'

'

'

'

'

'

900,000

'

2,600,000

'

'

13,800,000

9,400,000

Black Scholes inputs [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$14.92

'

$5.85

$14.92

'

$5.85

'

Exercise price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$2.45

'

$2.45

$3.08

'

$3.08

'

Risk free interest rate (in hundredths)

'

'

'

'

'

'

'

'

'

'

0.21%

'

0.25%

0.29%

'

0.31%

'

Volatility (in hundredths)

'

'

'

'

'

'

'

'

'

'

95.00%

'

100.00%

95.00%

'

112.00%

'

Expected term

'

'

'

'

'

'

'

'

'

'

'1 year 3 months

'

'2 years

'1 year 9 months

'

'2 years 6 months

'

Dividend (in hundredths)

'

'

'

'

'

'

'

'

'

'

0.00%

'

0.00%

0.00%

'

0.00%

'

Fair value adjustment of common stock warrants

6,044,000

-1,872,000

12,025,000

-995,000

'

'

'

'

'

'

2,500,000

700,000

'

9,500,000

-1,600,000

'

'

Activity of the warrant liabilities [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants, beginning of period

'

'

'

'

'

'

'

'

'

'

2,600,000

6,700,000

'

13,800,000

18,700,000

'

'

Warrants exercised

'

'

9,809,000

'

'

'

'

'

'

'

-4,200,000

-4,500,000

'

-13,900,000

-2,700,000

'

'

Adjustment to fair value of common stock warrants

6,044,000

-1,872,000

12,025,000

-995,000

'

'

'

'

'

'

2,500,000

700,000

'

9,500,000

-1,600,000

'

'

Fair value of warrants, end of period

10,300,000

17,300,000

10,300,000

17,300,000

'

'

'

'

'

'

900,000

2,900,000

2,600,000

9,400,000

14,400,000

13,800,000

'

Net loss

17,277,000

10,222,000

57,325,000

27,211,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of 10% decrease of closing stock price on increase (decrease) on net loss

'

'

-1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of 10% increase of closing stock price on increase (decrease) on net loss

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of 10% decrease of the volatility assumption on increase (decrease) on net loss

'

'

-100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of 10% increase of the volatility assumption on increase (decrease) on net loss

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Weighted-average exercise price

ACCRUED_LIABILITIES_Details

ACCRUED LIABILITIES (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued liabilities [Abstract]	'	'
Clinical trials and related costs	$2,022	$641
Employee bonuses and commissions	1,756	502
Commercial and administrative consulting	1,007	167
Salaries and employee benefits	1,106	742
Professional fees	815	67
Interest expense on loan	809	0
Revenue deductions	783	0
Manufacturing costs	533	0
Royalties	363	0
Other	66	31
Total accrued liabilities	$9,260	$2,150

STOCK_OPTION_PLANS_Details

STOCK OPTION PLANS (Details) (USD $)	3 Months Ended	9 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Aug. 31, 2012
			Stock Options [Member]	Stock Options [Member]	Stock Options [Member]	Stock Options [Member]
Assumptions of Black-Scholes option pricing model for stock-based compensation expense [Abstract]	'	'	'	'	'	'
Risk-free interest rate (in hundredths)	'	1.51%	1.51%	'	'	0.68%
Expected life of stock option	'	'5 years	'5 years	'	'	'5 years
Annual volatility (in hundredths)	'	67.18%	67.18%	'	'	124.90%
Dividend rate (in hundredths)	'	0.00%	0.00%	'	'	0.00%
Option shares [Roll Forward]	'	'	'	'	'	'
Outstanding, beginning of period (in shares)	'	'	8,336	7,885	7,791	'
Granted (in shares)	'	'	317	478	130	'
Exercised (in shares)	-370,352	-378,366	-370	0	-8	'
Canceled (in shares)	'	'	-53	-27	-28	'
Outstanding, end of period (in shares)	'	'	8,230	8,336	7,885	'
Weighted-average exercise price [Roll Forward]	'	'	'	'	'	'
Outstanding, beginning of period (in dollars per share)	'	'	$5.76	$5.76	$5.79	'
Granted (in dollars per share)	'	'	$11.06	$6.58	$5.39	'
Exercised (in dollars per share)	'	'	$4.07	$0	$0.85	'
Canceled (in dollars per share)	'	'	$38.14	$20.70	$13.94	'
Outstanding, end of period (in dollars per share)	'	'	$5.83	$5.76	$5.76	'
Exercisable [Roll Forward]	'	'	'	'	'	'
Outstanding, beginning of period (in shares)	'	'	4,525	4,031	3,494	'
Granted (in shares)	'	'	0	0	0	'
Exercised (in shares)	'	'	0	0	0	'
Canceled (in shares)	'	'	0	0	0	'
Outstanding, end of period (in shares)	'	'	4,653	4,525	4,031	'
Weighted-average fair value of options granted [Roll Forward]	'	'	'	'	'	'
Outstanding, beginning of period (in dollars per share)	'	'	$3.55	$3.47	$3.48	'
Granted (in dollars per share)	'	'	$5.32	$4.01	$3.04	'
Exercised (in dollars per share)	'	'	$3.27	$0	$0.62	'
Canceled (in dollars per share)	'	'	$0	$4.73	$4.25	'
Outstanding, end of period (in dollars per share)	'	'	$3.71	$3.55	$3.47	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'	'
Total unrecognized compensation cost	$14	$14	'	'	'	'
Weighted-average period over which compensation cost expected to be recognized	'	'3 years	'	'	'	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Jun. 10, 2013	Apr. 25, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'	'
Lease term	'	'7 years
Monthly rent payment	'	$19,460
Additional monthly rent payment	$1,870	'